Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
July 28, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 20, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
Via
Benzinga
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 15, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
June 16, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Raises $150M Via Equity Offering
April 27, 2022
Via
Benzinga
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
April 06, 2022
Via
Investor Brand Network
Short Volatility Alert: Deciphera Pharmaceuticals, Inc.
June 13, 2022
On Friday, shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) experienced volatile short activity. After the activity, the stock price moved down -5.45% to $11.27. The overall sentiment for DCPH...
Via
Benzinga
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
June 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
May 04, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Inc. (DCPH) Climbs to Annual-High Share Price
April 06, 2022
Via
Investor Brand Network
Preview: Deciphera Pharmaceuticals's Earnings
May 03, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Deciphera Pharmaceuticals Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
May 03, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
May 02, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
April 29, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
April 27, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 26, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
18 Stocks Moving in Tuesday's Pre-Market Session
April 26, 2022
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...
Via
Benzinga
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
April 13, 2022
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)
Via
Benzinga
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
April 12, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 06, 2022
Gainers
Via
Benzinga
Deciphera Pharmaceuticals Inc. Climbs To Annual-High Share Price
April 06, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
March 28, 2022
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 09, 2022
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
February 08, 2022
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For February 8, 2022
February 08, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.